David Kirn, MD, is co-founder and has served as Chief Executive Officer since inception in 2013. Dr. Kirn is also Professor of Bioengineering and Molecular & Cellular Biology (Adjunct) at UC Berkeley where he teaches biotechnology entrepreneurship, including in the Robinson Life Sciences Business & Entrepreneurship Program. He is a board director and co-Founder of the UC Berkeley Life Sciences Entrepreneurship Center.
Over his 30 year career, Dr. Kirn has co-founded and been CEO of four viral vector-based genetic medicines companies, three of which to date were either acquired or went public. Dr. Kirn also held senior clinical research and development positions at Onyx Pharmaceuticals (VP) and Celgene (SVP), and was a senior consultant and strategic advisor on viral vector-based genetic medicines to Novartis, Bayer, Pfizer, Biogen and others.
Dr. Kirn received a BA in Physiology (Departmental Citation; Phi Beta Kappa) from UC Berkeley, an MD (Alpha Omega Alpha) from UC San Francisco Medical School and completed internal medicine residency training at Harvard Medical School, Brigham & Women’s Hospital (including term as Chief Medical Resident at affiliated WRVA hospital). He completed medical oncology and clinical research fellowships at UC San Francisco, and he completed a certificate of business excellence from the Haas Business School at UC Berkeley. He was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center, was named to The Medicine Maker Power List, Advanced Medicine in 2022, and was a 2024 PharmaVoice 100 honoree in the Standout Leaders category.
What is David Kirn's net worth?
The estimated net worth of David Kirn is at least $11.85 million as of July 10th, 2024. Kirn owns 1,059,153 shares of 4D Molecular Therapeutics stock worth more than $11,851,922 as of December 5th. This net worth evaluation does not reflect any other assets that Kirn may own. Additionally, Kirn receives a salary of $1,010,000.00 as CEO at 4D Molecular Therapeutics. Learn More about David Kirn's net worth.
What is David Kirn's salary?
How do I contact David Kirn?
Has David Kirn been buying or selling shares of 4D Molecular Therapeutics?
David Kirn has not been actively trading shares of 4D Molecular Therapeutics during the last ninety days. Most recently, David Kirn sold 12,923 shares of the business's stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $22.49, for a transaction totalling $290,638.27. Following the completion of the sale, the chief executive officer now directly owns 1,059,153 shares of the company's stock, valued at $23,820,350.97. Learn More on David Kirn's trading history.
Who are 4D Molecular Therapeutics' active insiders?
Are insiders buying or selling shares of 4D Molecular Therapeutics?
During the last twelve months, insiders at the sold shares 5 times. They sold a total of 10,763 shares worth more than $109,414.60. The most recent insider tranaction occured on November, 17th when insider Scott Bizily sold 1,635 shares worth more than $17,314.65. Insiders at 4D Molecular Therapeutics own 9.6% of the company.
Learn More about insider trades at 4D Molecular Therapeutics. Information on this page was last updated on 11/17/2025.
